Holen Sie sich die Stockscreener-App
24.98
1.17%
0.29
Handel nachbörslich:
25.00
0.02
+0.08%
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Catalyst Pharmaceuticals, Inc. (CPRX) stock price, news, quote and history - Yahoo Finance UK
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - TradingView
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is It Too Late To Consider Catalyst Pharmaceuticals (CPRX) After Strong Multi Year Rerating? - sahmcapital.com
Catalyst Pharmaceuticals, Inc. (CPRX) latest stock news and headlines - Yahoo Finance Australia
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - TradingView
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - marketwatch.com
Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability? - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
New Strong Buy Stocks for March 31st - Yahoo Finance Singapore
Best Value Stocks to Buy for March 31st - Yahoo Finance Singapore
Aug Movers: Can Catalyst Pharmaceuticals Inc stock outperform in a bear marketEarnings Recap Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Trading And DCF Upside Signals - Yahoo Finance
Aug Mood: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Mixed Long Term And Recent Shareholder Returns - Sahm
Insider Buy: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Fundamental Recap & Long-Term Investment Growth Plans - baoquankhu1.vn
Total Market Plus Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - gurufocus.com
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - marketwatch.com
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes - TradingView
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Strong Buy" by Brokerages - MarketBeat
Vanguard realigns reporting; Catalyst Pharmaceuticals (CPRX) shows 0% ownership - Stock Titan
Truist Financial Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy" - MarketBeat
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Forecasts - Yahoo Finance
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - marketwatch.com
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
Will Catalyst Pharmaceuticals Inc benefit from government policyWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown - Sahm
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance Australia
Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan
Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):